Severe acute interstitial pneumonia and gefitinib

Akira Inoue, Yasuo Saijo, Makoto Maemondo, Kazunori Gomi, Yutaka Tokue, Yuichiro Kimura, Masahito Ebina, Toshiaki Kikuchi, Takuya Moriya, Toshihiro Nukiwa

研究成果: Article査読

444 被引用数 (Scopus)

抄録

Gefitinib is an oral selective inhibitor of the epidermal growth factor receptor tyrosine kinase that is an effective treatment for patients with advanced non-small cell lung cancer who do not respond to platinum-based chemotherapy. We assessed four patients who had non-small cell lung cancer causing severe acute interstitial pneumonia in association with gefitinib. Although two patients recovered after treatment with steroids, the other two died from progressive respiratory dysfunction. On the basis of autopsies and bilateral distribution of diffuse ground-glass opacities in chest CTs, we diagnosed diffuse alveolar damage, which was consistent with acute interstitial pneumonia. Patients with interstitial pneumonia also had other pulmonary disorders such as previous thoracic irradiation and poor performance status. Physicians should be aware of the alveolar damage induced by gefitinib, especially for patients with these characteristic features.

本文言語English
ページ(範囲)137-139
ページ数3
ジャーナルLancet
361
9352
DOI
出版ステータスPublished - 2003 1月 11

ASJC Scopus subject areas

  • 医学(全般)

フィンガープリント

「Severe acute interstitial pneumonia and gefitinib」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル